SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after achieving its first-ever quarterly profit amidst strong delivery growth, sparking fervent community discussion about a potential short squeeze and its long-term undervaluation given its unique battery swap technology and new chip innovations.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is highly volatile amid conflicting reports surrounding the Strait of Hormuz, ranging from US intelligence indications of potential Iranian mining to a retracted government claim of naval escorts. This geopolitical uncertainty, coupled with political statements about the Iran conflict nearing its end, is fueling community debate over market manipulation and global oil supply stability.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending with soaring investor enthusiasm, driven by its recently secured EPA, UK, and EU regulatory clearances for its ultra-pure graphene and strong anticipation of major commercial contracts and a NASDAQ uplisting. The community widely views the company as a potential leader for the "graphene age," poised to revolutionize diverse sectors from defense to AI data centers.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is trending following news of a $30M acceleration program for its Tanbreez Heavy Rare Earth project, fueling community debate about potential resource expansion and the upcoming Bankable Feasibility Study. Bulls foresee a significant re-rating in the strategically vital rare earth sector, while others eye the stock cautiously given past volatility and skepticism regarding prior economic assessments.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is seeing extreme volatility, with community discussion centered on conflicting reports about the Strait of Hormuz
Aquickly deleted government claim of a navy escort was followed by intelligence suggesting Iran is deploying mines, leading to sharp market swings and widespread accusations of manipulation.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following recent analyst upgrades and positive sentiment from its Barclays conference, where management highlighted AI integration and a clear strategy for BetterHelp's turnaround, with the community actively debating its perceived undervaluation and potential for a short squeeze as the turnaround narrative gains traction.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is experiencing high volume and robust discussion following strong Q4 earnings, which showed accelerated sales of its flagship rare disease drug, MIPLYFFA. The market is re-evaluating ZVRA's potential as it transitions to a profitable commercial-stage company, with many in the community anticipating further upside ahead of potential European approval.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is a top trending stock ahead of its crucial earnings report, sparking a fierce debate among investors over whether its substantial AI infrastructure investments will fuel significant cloud growth or exacerbate concerns about its rising debt and negative free cash flow. Conflicting reports regarding data center expansion plans with OpenAI and potential layoffs have further amplified market volatility and option activity.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech Inc. (CITR) is gaining attention as its CEO presents at the iAccess Alpha conference, driving community interest in the low-float stock's fire-retardant technology, which traders believe has significant potential in the growing market for fire prevention materials.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending after being selected for a White House-backed air taxi program and launching Uber Air services in Dubai, marking significant strides toward commercialization, while a rival's countersuit alleging undisclosed foreign ties and potential fraud ignites active community discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE

DLD Asset Management LP bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The...

Spyre Therapeutics, Inc. $SYRE Shares Sold by TD Asset Management Inc

TD Asset Management Inc decreased its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 36.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The...

Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of...

Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 2,500 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.65...

Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of...

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has earned an average rating of "Buy" from the ten ratings firms that are covering the company, Marketbeat reports. One equities research...

Spyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Spyre Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Wells Fargo & Company raised their price target on shares of Spyre Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Friday...

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Time to Buy?

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Here's Why...

Spyre Therapeutics (NASDAQ:SYRE) Receives Buy Rating from BTIG Research

BTIG Research reissued a "buy" rating and set a $70.00 price objective on shares of Spyre Therapeutics in a report on Friday...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

SYRE
Aeglea BioTherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SYRE News

SYREAeglea BioTherapeutics Inc